APM
JAZZ icon

Avidity Partners Management’s Jazz Pharmaceuticals JAZZ Stock Holding History

Avidity Partners Management’s Portfolio JAZZ Stock Details JAZZ Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q2 		– Sell
-80,000
Closed -$9.93M – 73
2025
Q1 		$9.93M Sell
80,000
-154,500
-66% -$20.2M 1.89% 16
2024
Q4 		$28.9M Sell
234,500
-196,500
-46% -$23.2M 2.84% 11
2024
Q3 		$48M Sell
431,000
-113,500
-21% -$12.4M 2.45% 9
2024
Q2 		$58.1M Sell
544,500
-39,500
-7% -$4.34M 2.47% 11
2024
Q1 		$70.3M Buy
584,000
+94,881
+19% +$11.6M 2.27% 10
2023
Q4 		$60.2M Sell
489,119
-308,381
-39% -$38.5M 2.19% 13
2023
Q3 		$103M Buy
797,500
+94,722
+13% +$12.6M 4.16% 2
2023
Q2 		$87.1M Buy
702,778
+24,878
+4% +$3.35M 3.04% 3
2023
Q1 		$99.2M Sell
677,900
-49,641
-7% -$7.34M 3.29% 5
2022
Q4 		$116M Buy
727,541
+409,241
+129% +$60M 2.51% 14
2022
Q3 		$42.4M Buy
318,300
+256,300
+413% +$39M 0.86% 38
2022
Q2 		$9.67M Buy
+62,000
New +$9.54M 0.22% 51

Other funds holding JAZZ

Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
LSV Asset Management
LSV Asset Management Chicago, Illinois $46.4B AUM 27.74% 1-Year Est. Return
Capital World Investors
Capital World Investors Los Angeles, California $733B AUM 35.63% 1-Year Est. Return
Dimensional Fund Advisors
Dimensional Fund Advisors Austin, Texas $481B AUM 30.42% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Ameriprise
Ameriprise Minneapolis, Minnesota $432B AUM 30.22% 1-Year Est. Return
JP Morgan Chase
JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return
EC
EcoR1 Capital San Francisco, California $2.36B AUM 204.53% 1-Year Est. Return
Fuller & Thaler Asset Management
Fuller & Thaler Asset Management San Mateo, California $29.7B AUM 43.33% 1-Year Est. Return

Avidity Partners Management's JAZZ Position: Q2 2025 in Review

Avidity Partners Management sold out of Jazz Pharmaceuticals (JAZZ) in Q2 2025, closing a stake of 80,000 shares — an estimated $9.93M sold.

Avidity Partners Management first reported a position in JAZZ in Q2 2022 and held it in 12 quarters. The position peaked at $116M in Q4 2022. 501 funds tracked by Wall St. Rank hold JAZZ as of Q2 2025.

  • Avidity Partners Management reported no remaining Jazz Pharmaceuticals position as of Q2 2025 after selling out during the quarter.
  • Avidity Partners Management sold 80,000 Jazz Pharmaceuticals shares in Q2 2025, an estimated $9.93M.
  • Avidity Partners Management first reported a position in Jazz Pharmaceuticals in Q2 2022 and held it in 12 quarters.
  • Avidity Partners Management's Jazz Pharmaceuticals position peaked at $116M in Q4 2022.
  • 501 funds tracked by Wall St. Rank held Jazz Pharmaceuticals as of Q2 2025.

Based on Avidity Partners Management's 13F filing for Q2 2025, filed 14 Aug 2025.